首页>
外国专利>
THE FGF19-CHOLESTYRAMINE (F-CME) TEST AS A TWO-STAGE METHOD FOR ROUTINE CANCER SCREENING
THE FGF19-CHOLESTYRAMINE (F-CME) TEST AS A TWO-STAGE METHOD FOR ROUTINE CANCER SCREENING
展开▼
机译:FGF19-胆甾胺(F-CME)试验作为常规癌症筛查的两阶段方法
展开▼
页面导航
摘要
著录项
相似文献
摘要
Disclosed is a two-staged, generalized cancer screening concept modeled closely after a suppression test. The test is blood based, and screens for elevated levels of Fibroblast Growth Factor 19 (FGF19), a cancer biomarker expressed across a majority of cancers, via standard enzyme-linked immunosorbent assay (ELISA). Unlike other biomarker-based blood tests that rely on a single-blood draw, the F-CME test validates cancer with a follow-up test using oral cholestyramine as the “suppression” drug.
展开▼